Get the Stockscreener App
41.81
7.44%
-3.36
After Hours:
41.99
0.18
+0.43%
Uniqure Nv stock is traded at $41.81, with a volume of 2.81M.
It is down -7.44% in the last 24 hours and up +56.24% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
See More
Previous Close:
$45.17
Open:
$45.99
24h Volume:
2.81M
Relative Volume:
1.34
Market Cap:
$2.87B
Revenue:
$18.09M
Net Income/Loss:
$-208.87M
P/E Ratio:
-11.90
EPS:
-3.5125
Net Cash Flow:
$-178.15M
1W Performance:
-14.85%
1M Performance:
+56.24%
6M Performance:
+78.75%
1Y Performance:
+192.79%
1-Day Range:
$41.15
$46.09
1-Week Range:
$41.15
$49.70
52-Week Range:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Name
Uniqure Nv
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
41.81 | 3.17B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Mizuho | Neutral → Outperform |
| Mar-09-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-03-26 | Downgrade | Mizuho | Outperform → Neutral |
| Mar-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure Nv Stock (QURE) Latest News
Precision Trading with Uniqure N.v. (QURE) Risk Zones - Stock Traders Daily
Price to earnings forward of uniQure N.V. – LSE:0EE0 - TradingView
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
Form 144 uniQure N.V. For: 30 June - Investing.com UK
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
uniQure (QURE) CMO auto-sells shares for RSU tax withholding, keeps stake - Stock Titan
Form 144 uniQure N.V. For: 30 June By Investing.com - Investing.com Canada
UniQure (NASDAQ: QURE) files Form 144 to sell 30,000 shares via Citigroup - Stock Titan
UniQure (NASDAQ: QURE) insider notice to sell 21,167 shares - Stock Titan
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Price to book forward of uniQure N.V. – SWB:UQ1 - TradingView
uniQure N.V. moves ahead with $225 million public offering. Capital raise reshapes the gene therapy - AD HOC NEWS
uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP - The National Law Review
QURE Maintained by HC Wainwright & Co. -- Price Target Raised to $80 - GuruFocus
Enterprise value to EBITDA forward of uniQure N.V. – SWB:UQ1 - TradingView
Enterprise value to revenue forward of uniQure N.V. – SWB:UQ1 - TradingView
Price to sales forward of uniQure N.V. – GETTEX:UQ1 - TradingView
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $80 - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Stockholders to Connect - The National Law Review
Price to earnings forward of uniQure N.V. – BMV:QURE/N - TradingView
UniQure surges on plans to seek US nod for gene therapy - MSN
uniQure N.V. Actuals & Estimates (BX:UQ1) - TradingView
Form 144 uniQure N.V. For: 26 June By Investing.com - Investing.com South Africa
Form 144 uniQure N.V. For: 26 June - Investing.com UK
uniQure NV | 4: Statement of changes in beneficial ownership of securities-Officer Kapusta Matthew C - Moomoo
uniQure (QURE) CEO Kapusta sells 35K shares after exercising options - Stock Titan
UniQure (QURE) files Rule 144 to sell 22,402 RSU shares; prior 45,000 sold - Stock Titan
Enterprise value to EBIT forward of uniQure N.V. – NASDAQ:QURE - TradingView
uniQure N.V. Actuals & Estimates (FWB:UQ1) - TradingView
QURE Maintained by Mizuho -- Price Target Raised to $68.00 - GuruFocus
Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment Gets Buy Rating - Streetwise Reports
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure N.V. Actuals & Estimates (LS:A1XDTV) - TradingView
uniQure (QURE) Is Up 6.1% After Equity Raise And FDA Backing For Accelerated HD FilingHas The Bull Case Changed? - simplywall.st
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure prices upsized $225M public offering of ordinary shares - MSN
Price to sales forward of uniQure N.V. – LSX:A1XDTV - TradingView
uniQure closes $259M public offering at $45.50 per share By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of uniQure N.V. – LSX:A1XDTV - TradingView
UniQure Closes $259 Million Stock Offering - marketscreener.com
uniQure closes $259M public offering at $45.50 per share - Investing.com
uniQure Closes $259 Million Public Offering of Ordinary Shares - Quiver Quantitative
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
UniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - marketscreener.com
uniQure raises $259M as underwriters buy more shares - Stock Titan
uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Kapusta (QURE) sells 28,716 shares after option exercise on 06/25/2026 - Stock Titan
Price to earnings forward of uniQure N.V. – LSX:A1XDTV - TradingView
Price to book forward of uniQure N.V. – LSX:A1XDTV - TradingView
Enterprise value to EBITDA forward of uniQure N.V. – LSX:A1XDTV - TradingView
Uniqure Nv Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure Nv Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Sale |
46.42 |
30,000 |
1,392,600 |
148,235 |
| Kaye Jack | Director |
Jun 30 '26 |
Option Exercise |
23.44 |
21,167 |
496,230 |
43,056 |
| Kaye Jack | Director |
Jun 30 '26 |
Sale |
46.44 |
21,167 |
983,030 |
25,996 |
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):